Live Earnings Conference Call: ANI Pharmaceuticals will host a live Q2 2025 earnings call on August 8, 2025 at 8:30AM ET. Follow this link to get details and listen to ANI Pharmaceuticals' Q2 2025 earnings call when it goes live. Get details. ANI Pharmaceuticals (ANIP) Short Interest Ratio & Short Volume $69.01 -0.08 (-0.12%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$69.20 +0.19 (+0.28%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ANI Pharmaceuticals Short Interest DataANI Pharmaceuticals (ANIP) has a short interest of 2.13 million shares. This marks a 5.97% increase in short interest from the previous month. The short interest ratio (days to cover) is 6.0, indicating that it would take 6.0 days of the average trading volume of 348,289 shares to cover all short positions.Current Short Interest2,130,000 sharesPrevious Short Interest2,010,000 sharesChange Vs. Previous Month+5.97%Dollar Volume Sold Short$136.32 millionShort Interest Ratio6.0 Days to CoverLast Record DateJuly 15, 2025Outstanding Shares21,660,000 sharesPercentage of Shares Shorted9.83%Today's Trading Volume780,529 sharesAverage Trading Volume348,289 sharesToday's Volume Vs. Average224% Short Selling ANI Pharmaceuticals? Sign up to receive the latest short interest report for ANI Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartANIP Short Interest Over TimeANIP Days to Cover Over TimeANIP Percentage of Float Shorted Over Time ANI Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/15/20252,130,000 shares $136.32 million +6.0%N/A6 $64.00 6/30/20252,010,000 shares $131.15 million No Change10.4%5.5 $65.25 6/15/20252,010,000 shares $125.75 million +5.8%10.4%5.2 $62.56 5/31/20251,900,000 shares $112.59 million +2.2%10.3%4.7 $59.26 5/15/20251,860,000 shares $110.73 million -7.0%10.1%4.5 $59.53 4/30/20252,000,000 shares $141.64 million -15.3%N/A5.3 $70.82 4/15/20252,360,000 shares $164.14 million -10.6%12.9%7.7 $69.55 3/31/20252,640,000 shares $176.75 million +2.3%14.4%8.9 $66.95 3/15/20252,580,000 shares $161.22 million +0.8%14.1%9.7 $62.49 2/28/20252,560,000 shares $158.44 million No Change13.9%10.3 $61.89 Get the Latest News and Ratings for ANIP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 2/15/20252,560,000 shares $150.84 million +13.3%13.9%11 $58.92 1/31/20252,260,000 shares $132.53 million -1.3%N/A9.1 $58.64 1/15/20252,290,000 shares $129.50 million +6.5%N/A8.9 $56.55 12/31/20242,150,000 shares $118.85 million -8.5%N/A8.5 $55.28 12/15/20242,350,000 shares $132.99 million +27.7%N/A9.3 $56.59 11/30/20241,840,000 shares $105.30 million -12.8%N/A6.3 $57.23 11/15/20242,110,000 shares $119.38 million -2.3%N/A6.7 $56.58 10/31/20242,160,000 shares $123.65 million +5.4%N/A7 $57.25 10/15/20242,050,000 shares $120.13 million -9.7%N/A5.8 $58.60 9/30/20242,270,000 shares $135.43 million +2.3%N/A6.5 $59.66 9/15/20242,220,000 shares $129.89 million -8.3%N/A6.4 $58.51 8/31/20242,420,000 shares $154.28 million +44.9%N/A8.1 $63.75 8/15/20241,670,000 shares $102.04 million +439.8%N/A6.8 $61.10 7/31/2024309,400 shares $20.33 million -20.7%N/A1.3 $65.72 7/15/2024390,000 shares $24.66 million +5.7%N/A2.5 $63.22 6/30/2024369,000 shares $23.50 million -2.0%N/A2.4 $63.68 6/15/2024376,500 shares $23.58 million +11.0%N/A2.5 $62.62 5/31/2024339,100 shares $22.01 million +65.9%N/A2.2 $64.90 5/15/2024204,400 shares $13.25 million -11.1%N/A1.3 $64.82 4/30/2024229,900 shares $15.17 million +7.7%N/A1.6 $66.00 4/15/2024213,500 shares $14.16 million +8.4%N/A1.5 $66.30 3/31/2024197,000 shares $13.62 million -24.7%N/A1.4 $69.13 3/15/2024261,600 shares $17.27 million +5.0%N/A1.9 $66.00 2/29/2024249,100 shares $16.86 million +16.7%N/A1.8 $67.67 2/15/2024213,400 shares $12.28 million -11.9%N/A1.7 $57.55 1/31/2024242,200 shares $13.52 million +8.2%N/A1.6 $55.82 1/15/2024223,900 shares $12.70 million -15.2%N/A1.4 $56.74 12/31/2023264,000 shares $14.56 million -34.0%N/A1.5 $55.14 12/15/2023399,700 shares $21.15 million -0.5%N/A2.3 $52.91 11/30/2023401,700 shares $20.01 million +6.6%N/A2.4 $49.81GENIUS Act: Cancel Your Money? (Ad)A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. Backed by the government but powered by private corporations, this initiative paves the way for digital dollars—programmable, trackable, and outside your control. Once embedded into apps, banks, and retail systems, opting out may no longer be possible. But there’s still time to protect your financial freedom—if you act before the system goes fully live.Get the free info kit with 3 strategies to sidestep digital dollar control. 11/15/2023376,800 shares $19.71 million -11.0%N/A2.2 $52.30 10/31/2023423,400 shares $26.14 million +1.9%N/A2.2 $61.74 10/15/2023415,400 shares $23.95 million -6.4%N/A2.5 $57.66 9/30/2023444,000 shares $25.78 million +44.9%N/A2.8 $58.06 9/15/2023306,500 shares $19.12 million +15.8%N/A2 $62.39 8/31/2023264,800 shares $17.05 million -7.5%N/A1.7 $64.39 8/15/2023286,200 shares $17.71 million -15.7%N/A2 $61.89 7/31/2023339,300 shares $17.83 million -2.0%N/A2.3 $52.55 7/15/2023346,200 shares $17.41 million +3.8%N/A2.5 $50.28 6/30/2023333,700 shares $17.96 million +21.8%N/A2.5 $53.83 6/15/2023274,000 shares $13.89 million +7.2%N/A2.2 $50.71 5/31/2023255,600 shares $11.54 million -24.1%N/A2.3 $45.14 5/15/2023336,900 shares $13.77 million -15.9%N/A3.2 $40.88 4/30/2023400,700 shares $15.11 million +14.7%N/A5.8 $37.72 4/15/2023349,500 shares $13.43 million +4.7%N/A5.5 $38.42 3/31/2023333,800 shares $13.26 million -3.9%2.6%5.1 $39.72 3/15/2023347,200 shares $13.89 million +15.3%N/A5.1 $40.01 2/28/2023301,100 shares $12.60 million -4.6%N/A4.5 $41.84 2/15/2023315,500 shares $14.21 million -4.3%N/A4.7 $45.04 1/31/2023329,600 shares $14.74 million +1.2%N/A4.5 $44.73 1/15/2023325,700 shares $14.31 million -4.9%N/A4.6 $43.95 12/30/2022342,300 shares $13.77 million -20.0%N/A5 $40.23 12/15/2022427,700 shares $16.78 million -4.3%N/A6.5 $39.24 11/30/2022447,000 shares $18.75 million -11.0%N/A6.7 $41.95 11/15/2022502,200 shares $18.38 million -12.5%4.0%7.5 $36.60 10/31/2022573,700 shares $22.14 million +1.0%4.6%8.8 $38.59 10/15/2022568,000 shares $18.87 million -15.3%4.5%8.4 $33.22 9/30/2022670,700 shares $21.56 million -2.7%5.4%9.1 $32.14 9/15/2022689,200 shares $25.10 million -1.0%5.5%8 $36.42 8/31/2022696,200 shares $25.68 million +4.4%5.6%7.6 $36.89 8/15/2022667,100 shares $25.24 million -2.6%5.4%7.1 $37.84 7/31/2022685,000 shares $23.46 million -4.8%7.8%6.6 $34.25 7/15/2022719,400 shares $22.55 million -12.3%8.2%6.5 $31.35 6/30/2022820,000 shares $24.33 million +17.9%9.3%7.3 $29.67 6/15/2022695,400 shares $16.53 million +2.5%7.9%6 $23.77 5/31/2022678,700 shares $20.53 million +6.1%5.5%4.8 $30.25 5/15/2022639,900 shares $16.94 million +9.5%5.2%4.4 $26.47 4/30/2022584,300 shares $17.24 million +9.3%4.7%4.2 $29.51 4/15/2022534,600 shares $17.19 million +4.2%4.3%3.8 $32.16 3/31/2022513,200 shares $14.43 million +65.0%4.2%3.9 $28.11 3/15/2022311,000 shares $9.02 million -12.0%2.5%2.3 $29.01 2/28/2022353,400 shares $13.23 million +8.6%2.9%3.1 $37.45 2/15/2022325,300 shares $13.09 million -8.8%2.7%2.7 $40.25 1/31/2022356,700 shares $14.42 million +22.5%2.9%2.6 $40.42 1/15/2022291,100 shares $12.53 million +13.3%2.4%1.3 $43.03 12/31/2021257,000 shares $11.84 million +3.1%2.1%1.1 $46.08 12/15/2021249,200 shares $11.68 million +15.8%2.1%1.1 $46.86 11/30/2021215,200 shares $8.85 million -7.9%1.9%1.1 $41.14 11/15/2021233,600 shares $10.51 million -53.1%2.1%1.3 $45.01 10/29/2021497,700 shares $18.60 million +4.3%4.5%3 $37.38The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 10/15/2021477,200 shares $18.39 million -4.9%4.8%8 $38.54 9/30/2021501,900 shares $16.47 million -0.3%5.1%8.5 $32.82 9/15/2021503,200 shares $13.78 million +5.4%5.1%8.3 $27.39 8/31/2021477,300 shares $14.48 million +2.5%4.8%8.1 $30.33 8/13/2021465,600 shares $13.99 million +2.2%4.7%8.1 $30.05 7/30/2021455,400 shares $15.45 million -1.7%4.6%7.5 $33.93 7/15/2021463,300 shares $15.28 million +5.5%4.7%7.9 $32.98 6/30/2021439,300 shares $15.40 million -11.9%4.5%7.4 $35.05 6/15/2021498,500 shares $17.07 million -1.5%5.1%8.6 $34.24 5/28/2021505,900 shares $17.38 million +3.9%5.1%8.6 $34.35 5/14/2021486,900 shares $16.33 million -3.0%4.9%8 $33.53 4/30/2021502,000 shares $16.74 million -4.8%5.1%8.4 $33.35 4/15/2021527,300 shares $17.77 million +3.1%5.5%9.4 $33.70 3/31/2021511,700 shares $16.86 million -3.1%5.5%9.1 $32.94 3/15/2021528,100 shares $17.08 million -2.7%5.6%8.2 $32.34 2/26/2021542,800 shares $16.07 million +4.1%5.7%8.7 $29.60 2/12/2021521,300 shares $16.30 million -2.6%5.5%8.1 $31.26 1/29/2021535,100 shares $15.80 million +4.1%5.6%7.5 $29.52 1/15/2021514,000 shares $16.50 million -8.6%5.4%7 $32.10 12/31/2020562,500 shares $16.11 million -6.3%5.9%7.7 $28.64 12/15/2020600,400 shares $17.98 million -2.1%6.3%8.5 $29.95 11/30/2020613,000 shares $18.07 million +2.1%6.4%8.9 $29.48 11/15/2020600,700 shares $16.70 million -8.2%6.3%8.6 $27.80 10/30/2020654,200 shares $17.22 million +22.5%6.9%9.1 $26.32 10/15/2020534,100 shares $15.49 million -2.9%5.6%7.2 $29.00 9/30/2020550,000 shares $15.52 million -0.3%5.8%6.6 $28.21 9/15/2020551,800 shares $15.64 million -10.4%5.8%5.8 $28.35 8/31/2020615,700 shares $19.31 million -1.6%6.5%5.8 $31.36 8/14/2020625,900 shares $20.28 million -1.9%6.6%4.9 $32.40 ANIP Short Interest - Frequently Asked Questions What is ANI Pharmaceuticals' current short interest? Short interest is the volume of ANI Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of July 15th, investors have sold 2,130,000 shares of ANIP short. Learn More on ANI Pharmaceuticals' current short interest. What is a good short interest ratio for ANI Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ANIP shares currently have a short interest ratio of 6.0. Learn More on ANI Pharmaceuticals's short interest ratio. Which institutional investors are shorting ANI Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of ANI Pharmaceuticals: Simplex Trading LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is ANI Pharmaceuticals' short interest increasing or decreasing? ANI Pharmaceuticals saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 2,130,000 shares, an increase of 6.0% from the previous total of 2,010,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does ANI Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to ANI Pharmaceuticals: ADMA Biologics Inc (6.06%), Annovis Bio, Inc. (12.62%), Nuvalent, Inc. (12.35%), CRISPR Therapeutics AG (27.82%), Rhythm Pharmaceuticals, Inc. (7.53%), Lantheus Holdings, Inc. (12.25%), Axsome Therapeutics, Inc. (7.27%), Vaxcyte, Inc. (10.56%), Merus N.V. (6.56%), Cytokinetics, Incorporated (13.64%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Coinbase Global, Inc. ($5.11 billion), Charter Communications, Inc. ($4.76 billion), Reddit Inc. ($2.84 billion), SoFi Technologies, Inc. ($2.79 billion), Seagate Technology Holdings PLC ($2.79 billion), Live Nation Entertainment, Inc. ($2.67 billion), Rocket Lab Corporation ($2.49 billion), AST SpaceMobile, Inc. ($2.12 billion), Moderna, Inc. ($2.09 billion), and Omnicom Group Inc. ($2.04 billion). View all of the most shorted stocks. What does it mean to sell short ANI Pharmaceuticals stock? Short selling ANIP is an investing strategy that aims to generate trading profit from ANI Pharmaceuticals as its price is falling. ANIP shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against ANI Pharmaceuticals? A short squeeze for ANI Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ANIP, which in turn drives the price of the stock up even further. How often is ANI Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ANIP, twice per month. The most recent reporting period available is July, 15 2025. More Short Interest Resources from MarketBeat Related Companies ADMA Biologics Short Interest Annovis Bio Short Interest Nuvalent Short Interest CRISPR Therapeutics Short Interest Rhythm Pharmaceuticals Short Interest Lantheus Short Interest Axsome Therapeutics Short Interest Vaxcyte Short Interest Merus Short Interest Cytokinetics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ANIP) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
